logo
  

NVIDIA Q1 Profit Rises

Technology company NVIDIA Corp. (NVDA) on Wednesday reported first-quarter net income of $1.91 billion or $3.03 per share, higher than $917 million or $1.47 per share in the previous-year period.

Net income, excluding certain items, was $2.31 billion or $3.66 per share, compared to $1.12 billion or $1.80 per share in the same period a year ago. On average, 30 analysts polled by Thomson Reuters expected the company to post earnings of $3.28 per share in the quarter. Analysts' estimates, usually exclude, one-time items.

During the three-month period, revenues rose 84 percent to $5.66 billion from $3.08 billion in the first quarter of last year, while analysts were looking for revenues of $5.41 billion.

Looking ahead, in the second quarter, the company expects revenues of $6.30 billion, plus or minus 2 percent, while analysts expect revenues of $5.5 billion in the period.

The company will pay its next cash dividend of $0.16 per share on July 1, to all shareholders of record on June 10.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Salt Lake City, Utah-based Huish Outdoors is recalling Oceanic Adult Dry Top Snorkels sold exclusively at Costco citing risk for drowning, U.S. Consumer Product Safety Commission said. The recall involves about 76,000 units of Oceanic Adult Dry Top Snorkels. The recall was initiated after Oceanic received 13 reports of the snorkels leaking. Boeing expects Europe's commercial aviation fleet to need 8,705 new airplanes through 2040 to cater to the growing leisure travel market in the region and fleet replacements with more fuel-efficient models, according to the Boeing's 2021 Commercial Market Outlook (CMO), an annual forecast of long-term demand for commercial airplanes and services. The U.S. Food and Drug Administration authorized marketing of a software developed by Paige.AI, a provider of AI-based digital diagnostics, which could help pathologists to identify prostate cancer. The software, called Paige Prostate, is the first and only artificial intelligence or AI-based pathology product to receive FDA approval for in vitro diagnostic or IVD use in detecting cancer...
Follow RTT